Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

Journal of Hepatology

Volumn 54, Issue 6, 2011, Pages 1250-1262

  Khattab, Mahmoud A ^a   Ferenci, Peter ^b   Hadziyannis, Stephanos J ^c   Colombo, Massimo ^d   Manns, Michael P ^e   Almasio, Piero L ^f   Esteban, Rafael ^g   Abdo, Ayman A ^h   Harrison, Stephen A ⁱ   Ibrahim, Nazir ^j   Cacoub, Patrice ^k   Eslam, Mohammed ^a   Lee, Samuel S ^l  

^a MINIA UNIVERSITY   (Egypt)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c HENRY DUNANT HOSPITAL   (Greece)

^d UNIVERSITY OF MILAN   (Italy)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF PALERMO   (Italy)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h KING SAUD UNIVERSITY   (Saudi Arabia)

ⁱ BROOKE ARMY MEDICAL CENTER   (United States)

^j University of Kalamoon   (Syrian Arab Republic)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BOCEPREVIR; INTERLEUKIN 28B; MERICITABINE; NITAZOXANIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PIOGLITAZONE; RIBAVIRIN; SILIBININ; TELAPREVIR; VIRUS RNA;

ANTIVIRAL THERAPY; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; FATTY LIVER; GENOTYPE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEDICAL HISTORY; MIXED INFECTION; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SCHISTOSOMIASIS; SINGLE NUCLEOTIDE POLYMORPHISM; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS GENE; VIRUS LOAD;

EID: 79956074037     PISSN: 01688278     EISSN: 01688278     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.11.016     Document Type: Review

References (144)

1. N. Ogata, H.J. Alter, R.H. Miller, and R.H. Purcell Nucleotide sequence and mutation rate of the H strain of hepatitis C virus Proc Natl Acad Sci USA 88 8 1991 3392 3396 (Pubitemid 21916627)
2. P. Simmonds, A. Alberti, H.J. Alter, F. Bonino, D.W. Bradley, and C. Brechot A proposed system for the nomenclature of hepatitis C viral genotypes Hepatology 19 5 1994 1321 1324 (Pubitemid 24134259)
3. C. Kuiken, and P. Simmonds Nomenclature and numbering of the hepatitis C virus Methods Mol Biol 510 2009 33 53
4. H.J. Hnatyszyn Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes Antiviral Ther 10 2005 1 11 (Pubitemid 40767627)
5. World Health Organization. Hepatitis C. Geneva, Switzerland: World Health Organization, 2000 WHO fact sheet 164. Available at http://www.who.int/ mediacentre/factsheets/fs164/en/print.html. Accessed 1 August 2010.
6. M.H. Nguyen, and E.B. Keeffe Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6 Clin Gastroenterol Hepatol 3 Suppl. 2 2005 S97 S101
7. Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report: 2007. Available at http://www.mohp.gov. eg/Main.asp (accessed 6 July 2010).
8. F. Abdel-Aziz, M. Habib, M.K. Mohamed, M. Abdel-Hamid, F. Gamil, and S. Madkour Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence Hepatology 32 2000 111 115 (Pubitemid 30432374)
9. A. Elkady, Y. Tanaka, F. Kurbanov, F. Sugauchi, M. Sugiyama, and A. Khan Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication J Med Virol 81 6 2009 1015 1023
10. C. Frank, M.K. Mohamed, G.T. Strickland, D. Lavanchy, R.R. Arthur, and L.S. Magder The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt Lancet 355 2000 887 912
11. Y. Tanaka, S. Agha, N. Saudy, F. Kurbanov, E. Orito, and T. Kato Exponential spread of hepatitis C virus genotype 4a in Egypt J Mol Evol 58 2004 191 195 (Pubitemid 38183970)
12. S.K. Stoszek, M. Abdel-Hamid, S. Narooz, M. El Daly, D.A. Saleh, and N. Mikhail Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women Trans R Soc Trop Med Hyg 100 2006 102 107 (Pubitemid 43024765)
13. S. El Katsha, S. Labeeb, S. Watts, and A. Younis Informal health providers and the transmission of hepatitis C virus: pilot study in two Egyptian villages East Mediterr Health J 12 2006 758 767 (Pubitemid 46358270)
14. M. Talaat, A. Kandeel, W. El-Shoubary, C. Bodenschatz, I. Khairy, and S. Oun Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt Am J Infect Control 31 2003 469 474 (Pubitemid 37533215)
15. L.S. Magder, A.D. Fix, N.N. Mikhail, M.K. Mohamed, M. Abdel-Hamid, and F. Abdel-Aziz Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data Int J Epidemiol 34 2005 160 165 (Pubitemid 40347388)
16. M.K. Mohamed, M. Abdel-Hamid, N.N. Mikhail, F. Abdel-Aziz, A. Medhat, and L.S. Magder Intrafamilial transmission of hepatitis C in Egypt Hepatology 42 2005 683 687 (Pubitemid 41233662)
17. F.Z. Al-Faleh Changing pattern of hepatitis viral infection in Saudi Arabia in the last two decades Ann Saudi Med 23 6 2003 367 371 (Pubitemid 37527007)
18. A.I. Sharara, S. Ramia, F. Ramlawi, J.E. Fares, S. Klayme, and R. Naman Genotypes of hepatitis C virus (HCV) among Lebanese patients: comparison of data with that from other middle Eastern countries Epidemiol Infect 135 2007 427 432 (Pubitemid 46443428)
19. N. Antaki, M. Haddad, K. Kebbewar, J. Abdelwahab, O. Hamed, and R. Aaraj The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province Epidemiol Infect 17 2008 1 6
20. S. Bdour Hepatitis C virus infection in Jordanian hemodialysis units: serological diagnosis and genotyping J Med Microbiol 51 2002 700 704 (Pubitemid 34804296)
21. R. Njouom, E. Nerrienet, M. Dubois, G. Lachenal, D. Rousset, and A. Vessie're The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960 Infect Genet Evol 7 2007 361 367 (Pubitemid 46667769)
22. L.-Z. Xu, D. Larzul, E. Delaporte, C. Bŕechot, and D. Kremsdorf Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon) J Gen Virol 75 1994 2393 2398 (Pubitemid 24282254)
23. J. Ndjomou, O.G. Pybus, and B. Matz Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon J Gen Virol 84 2003 2333 2341 (Pubitemid 37063121)
24. M.H. Wansbrough-Jones, E. Frimpong, B. Cant, K. Harris, M.R. Evans, and C.G. Teo Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana Trans R Soc Tropical Med Hyg 92 1998 496 499 (Pubitemid 28486470)
25. S. Kamal, and I. Nasser Hepatitis C genotype 4: what we know and what we don't yet know Hepatology 47 2008 1371 1383 (Pubitemid 351547923)
26. J.I. Esteban, S. Sauleda, and J. Quer The changing epidemiology of hepatitis C virus infection in Europe J Hepatol 48 2008 148 162 (Pubitemid 350191999)
27. A. Katsoulidou, V. Sypsa, N.C. Tassopoulos, J. Boletis, A. Karafoulidou, and I. Ketikoglou Molecular epidemiology of hepatitis C virus (HCV) in Greece. temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates J Viral Hepat 13 2006 19 27
28. C. Payan, F. Roudot-Thoraval, P. Marcellin, N. Bled, G. Duverlie, and I. Fouchard-Hubert Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: the GEMHEP Geno CII Study J Viral Hepat 12 2005 405 413 (Pubitemid 40961481)
29. F. Ansaldi, B. Bruzzone, S. Salamaso, M.C. Rota, P. Durando, and R. Gasparini Different seroprelavence and molecular epidemiology pattern of hepatitis C virus infection in Italy J Med Virol 76 2005 327 332 (Pubitemid 40770887)
30. N. Fernandez-Arcas, J. Lopez-Siles, S. Trapero, A. Ferraro, A. Ibanez, and F. Orihuela High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses J Med Virol 78 2006 1429 1435 (Pubitemid 44533871)
31. S. Franco, C. Tural, B. Clotet, and M.A. Martínez Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1 Virus Res 123 2007 161 169 (Pubitemid 46054337)
32. O.V. Nainan, M.J. Alter, D. Kruszon-Moran, F.X. Gao, G. Xia, and G. McQuillan Hepatitis C genotypes and viral concentrations in participants of general population survey in the United States Gastroenterology 131 2006 478 484 (Pubitemid 44142463)
33. N. Zein, J. Rakela, E. Krawitt, K.R. Reddy, T. Tominaga, and D.H. Persing Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy Ann Int Med 125 1996 634 639 (Pubitemid 126450598)
34. N. Antaki, A. Crax, S.M. Kamal, M. Moucari, S. Van der Merwe, and S. Haffar The neglected hepatitis C virus genotype 4, 5 and 6: an international consensus report Liver Int 30 2010 342 355
35. S. Zakaria, R. Fouad, O. Shaker, S. Zaki, A. Hashem, and S.S. El-Kamary Changing patterns of acute viral hepatitis at a major urban referral center in Egypt Clin Infect Dis 44 2007 e30 e36
36. J.M. Micallef, J.M. Kaldor, and G.J. Dore Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies J Viral Hepat 13 2006 34 41
37. S.M. Kamal, K.N. Moustafa, J. Chen, J. Fehr, A. Abdel Moneim, and K.E. Khalifa Duration of peginterferon therapy in acute hepatitis C: a randomised trial Hepatology 43 2006 923 931 (Pubitemid 43724617)
38. S.M. Kamal, J.W. Rasenack, L. Bianchi, A. Al Tawil, K. El Sayed Khalifa, and T. Peter Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4 (+) T-cell and cytokine response Gastroenterology 121 2001 646 656 (Pubitemid 32822580)
39. D. Roulot, V. Bourcier, V. Grando, P. Deny, Y. Baazia, and H. Fontaine Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection J Viral Hepat 14 2007 460 467 (Pubitemid 46944469)
40. R. Moucari, M.P. Ripault, M. Martinot-Peignoux, H. Voitot, A.C. Cardoso, and C. Stern Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4 Gut 59 3 2009 418
41. L. Gambotti, D. Batisse, N. Colin-de-Verdiere, E. Delaroque-Astagneau, J.C. Desenclos, and S. Dominguez Acute Hepatitis C collaborating Group. Acute Hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004 Euro Surveill 10 2005 115 117
42. S.M. Kamal, C.S. Graham, Q. He, L. Bianchi, A.A. Tawil, and J.W. Rasenack Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis J Infect Dis 189 2004 1140 1150 (Pubitemid 38457236)
43. S.M. Kamal, B. Turner, Q. He, J. Rasenack, L. Bianchi, and A. Al Tawil Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum marker of fibrosis Hepatology 43 2006 771 779
44. M. Abdel-Hamid, M. El-Daly, V. Molnegren, S. El-Kafrawy, S. Abdel-Latif, and G. Esmat Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma J Gen Virol 88 2007 1526 1531 (Pubitemid 46723235)
45. M. Abdel-Wahab, M. Mostafa, M. Sabry, M. el-Farrash, and T. Yousef Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center study Hepatogastroenterology 55 86-87 2008 1754 1759
46. W.A. Anwar, H.M. Khaled, H.A. Amra, H. El-Nezami, and C.A. Loffredo Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention Mutat Res 659 2008 176 184
47. S. Ezzat, M. Abdel-Hamid, S.A. Eissa, N. Mokthar, N.A. Labib, and L. El-Ghorory Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt Int J Hyg Environ Health 208 2005 329 339 (Pubitemid 41207425)
48. D.E. Kleiner The liver biopsy in chronic hepatitis C: a view from the other side of the microscope Semin Liver Dis 25 2005 52 64 (Pubitemid 40322350)
49. T. Asselah, L. Rubbia-Brandt, P. Marcellin, and F. Negro Steatosis in chronic hepatitis C: why does it really matter? Gut 55 1 2006 123 130 (Pubitemid 41820647)
50. M.A. Khattab, M.E. Abdel-Fattah, M. Eslam, A. Abdelaleem, R.A. Abdelaleem, and M. Shatat Hepatic Steatosis in Genotype 4 Chronic Hepatitis C Patients: Implication for Therapy J Clin Gastroenterol 44 10 2010 707 712
51. J.K. Olynyk, K.R. Reddy, A.M. Di Bisceglie, L.J. Jeffers, T.I. Parker, and J.L. Radick Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C Gastroenterology 108 1995 1104 1109
52. E. Tsochatzis, G.V. Papatheodoridis, E.K. Manesis, N. Chrysanthos, G. Kafiri, and K. Petraki Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors Am J Gastroenterol 102 2007 634 641 (Pubitemid 46328141)
53. S.M. Kamal, S.S. El Kamary, M.D. Shardell, M. Hashem, I.N. Ahmed, and M. Muhammadi Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response Hepatology 46 2007 1732 1740
54. T. Sestre, M. Nkuize, R. Moucari, M. Van Gossum, M. Reynders, and R. Scheen Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity Liver Int 30 2010 1131 1136
55. A. Lonardo, P. Loria, L.E. Adinolfi, N. Carulli, and G. Ruggiero Hepatitis C and steatosis: a reappraisal J Viral Hepat 13 2006 73 80
56. F. Negro, and A.J. Sanyal Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data Liver Int 29 Suppl 2 2009 26 37
57. G. Esmat, M. Metwally, K.R. Zalata, S. Gadalla, M. Abdel-Hamid, and A. Abouzied Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C J Hepatol 46 4 2007 620 627 (Pubitemid 46402951)
58. H.B. El-Serag Hepatocellular carcinoma: an epidemiologic view J Clin Gastroenterol 35 2 2002 S72 S78
59. M. Colombo Screening and diagnosis of hepatocellular carcinoma Liver Int 29 Suppl 1 2009 143 147
60. A.R. El-Zayadi, H.M. Badran, E.M. Barakat, D. Attia Mel, S. Shawky, and M.K. Mohamed Hepatocellular carcinoma in Egypt: a single center study over a decade World J Gastroenterol 11 2005 5193 5198 (Pubitemid 41410338)
61. M.M. Hassan, A.S. Zaghloul, H.B. El-Serag, O. Soliman, Y.Z. Patt, and C.L. Chappell The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients J Clin Gastroenterol 33 2001 123 126 (Pubitemid 32685921)
62. G.T. Strickland, H. Elhefni, T. Salman, I. Waked, M. Abdel-Hamid, and N.N. Mikhail Role of hepatitis C infection in chronic liver disease in Egypt Am J Trop Med Hyg 67 2002 436 442 (Pubitemid 35303870)
63. Freedman LS, Edwards BK, Ries LAG, Young JL, eds. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the middle east cancer consortium (MECC) compared with US SEER. National Cancer Institute. Bethesda, MD: NIH Pub. No. 06-5873, 2006.
64. National Cancer Registry of Egypt. Magnitude of hepatocellular carcinoma in Egypt. Available at: http://www.nci.edu.eg. Accessed 6 August 2010.
65. V. Bhattacherjee, L.E. Prescott, I. Pike, B. Rodgers, H. Bell, and A.R. El-Zayadi Use of NS-4 peptides to identify type specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6 J Gen Virol 76 1995 1737 1748
66. M. Angelico, E. Renganathan, C. Gandin, M. Fathy, M.C. Profili, and W. Refai Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections J Hepatol 26 1997 236 243 (Pubitemid 27077419)
67. S. Kamal, M. Madwar, L. Bianchi, A.E. Tawil, R. Fawzy, and T. Peters Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni Liver 20 2000 281 289 (Pubitemid 30488534)
68. E.M. Lehman, and M.L. Wilson Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis Int J Cancer 124 3 2009 690 697
69. S.H. Ryu, X. Fan, Y. Xu, T. Elbaz, A.R. Zekri, and A.O. Abdelaziz Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in Egypt J Med Virol 81 5 2009 844 847
70. M.S. Hifnawy, A.M. Mangoud, M.H. Eissa, E. Nor Edin, Y. Mostafa, and Y. Abouel-Magd The role of aflatoxin-contaminated food materials and HCV in developing hepatocellular carcinoma in Al-Sharkia Governorate, Egypt J Egypt Soc Parasitol 34 2004 479 488
71. H. Zylberberg, M.L. Chaix, and C. Brechot Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha Ann Intern Med 132 2000 845 846 (Pubitemid 30317811)
72. A. El-Zayadi, P. Simmonds, H. Dabbous, L. Prescott, O. Selim, and A. Ahdy Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4 J Viral Hepat 3 1996 261 264 (Pubitemid 126733926)
73. F. Hasan, H. Asker, J. Al-Khaldi, I. Siddique, M. Al-Ajmi, and S. Owaid Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 Am J Gastroenterol 99 2004 1733 1737 (Pubitemid 39237501)
74. O.A. Shobokshi, F.E. Serebour, L. Skakni, and M. Al Khalifa Combination therapy of peginterferon alfa-2a and ribavirin significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia Hepatology 38 2003 996A [Abstract]
75. G. Esmat, A.M. Abouzied, F. Abdel-Aziz, and T. Strickland Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin Hepatology 38 2003 324A [Abstract]
76. J. Al Ali, S. Owayed, W. Al-Qabandi, K. Husain, and F. Hasan Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents Ann Hepatol 9 2010 156 160
77. M. Khattab, M. Eslam, M.A. Sharwae, M. Shatat, A. Ali, and L. Hamdy Insulin resistance predicts rapid virologic response to Peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients Am J Gastroenterol 105 9 2010 1970 1977
78. M. Khattab, M. Emad, A. Abdelaleem, M. Eslam, R. Atef, and Y. Shaker Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance Liver Int 30 2010 447 454
79. H. El Makhzangy, G. Esmat, M. Said, M. Elraziky, S. Shouman, and R. Refai Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4 J Med Virol 81 9 2009 1576 1583
80. Y. Dahlan, H.M. Ather, M. Al-ahmadi, F. Batwa, and W. Al-hamoudi Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population World J Gastroenterol 15 35 2009 4429 4433
81. I.S. Elefsiniotis, E. Vezali, C. Mihas, and G. Saroglou Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin Intervirology 52 5 2009 247 251
82. R. Varghese, J. Al-Khaldi, H. Asker, A.A. Fadili, J. Al Ali, and F.A. Hassan Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin Hepatogastroenterology 56 89 2009 218 222
83. J.F. Rossignol, A. Elfert, Y. El-Gohary, and E.B. Keeffe Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin Gastroenterology 136 2009 856 862
84. P. Ferenci, H. Laferl, T.M. Scherzer, M. Gschwantler, A. Maieron, and H. Brunner Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response Gastroenterology 135 2008 451 458
85. Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, et al. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. J Viral Hepat. 2008 May 15.
86. M.F. Derbala, S.R. Al Kaabi, N.Z. El Dweik, F. Pasic, M.T. Butt, and R. Yakoob Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage World J Gastroenterol 12 2006 5692 5698 (Pubitemid 44594046)
87. A.R. El Zayadi, M. Attia, E.M. Barakat, H.M. Badran, H. Hamdy, and A. El-Tawil Response of hepatitis C genotype-4 naive patients to 24 weeks of peg-interferon-a2b/ribavirin or induction-dose interferon a2b/ribavirin/ amantadine: a non-randomized controlled study Am J Gastroenterol 100 2005 2447 2452
88. S.M. Kamal, A.A. El Tawil, T. Nakano, Q. He, J. Rasenack, and S.A. Hakam Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response Gut 54 2005 858 866 (Pubitemid 40732106)
89. F.A.I. Thakeb, M.M. Omar, M.M. El Awadi, and S.Y. Isshak Randomized controlled trial of peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus genotype 4 among Egyptian patients Hepatology 38 2003 252A [Abstract]
90. M. Diago, T. Hassanein, J. Rodes, A.M. Ackrill, and F. Sedarati Optimized virologic response in hepatitis C virus genotype 4 with peginterferon alpha2a and ribavirin Ann Intern Med 140 2004 72 73 (Pubitemid 38055932)
91. F.Z. Alfaleh, Q. Hadad, M.S. Khuroo, A. Aljumah, A. Algamedi, and H. Alashgar Peginterferon a-2b plus ribavirin compared with interferona-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4 Liver Int 24 2004 568 574 (Pubitemid 40028608)
92. L. Martín-Carbonero, M. Puoti, J. García-Samaniego, A. De Luca, E. Losada, and G. Quinzan Response to pegylated interferon plus ribavirin in HIV infected patients with chronic hepatitis C due to genotype 4 J Viral Hepat 15 2008 710 715
93. N.I. Rallón, S. Naggie, J.M. Benito, J. Medrano, C. Restrepo, and D. Goldstein Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients AIDS 24 8 2010 F23 F29
94. S.M. Kamal Hepatitis C genotype 4: increasing options and improving outcomes Liver Int 29 2009 39 48
95. Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of the IL28B-genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2010 [Epub ahead of print].
96. J.L. Dienstag, and J.G. McHutchison American Gastroenterological Association technical review on the management of hepatitis C Gastroenterology 130 2006 231 264 (Pubitemid 43049856)
97. APASL Consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. APASL Hepatitis C Working Party, et al. J Gastroenterol Hepatol 2007;22L615-33.
98. S.J. Hadziyannis, H. Sette Jr, T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
99. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Gonales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
100. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
101. P. Ferenci, M.W. Fried, M.L. Shiffman, C.I. Smith, G. Marinos, and F.L. Gonales Jr Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 2005 425 433 (Pubitemid 41111423)
102. P. Ferenci, H. Laferl, T.M. Scherzer, A. Andreas Maieron, H. Hofer, and R. Stauber Peginterferon α-2a/ribavirin for 72 weeks reduces relapse among Hepatitis C type 1 and 4 patients with early virologic responses Gastroenterology 138 2010 503 512
103. S. Bruno, T. Stroffolini, M. Colombo, S. Bollani, L. Benvegn, and G. Mazzella Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587 (Pubitemid 46453759)
104. M. Derbala, A. Amer, A. Bener, A.C. Lopez, M. Omar, and M. El Ghannam Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis J Viral Hepat 12 2005 380 385 (Pubitemid 40961477)
105. S. Males, R.R. Gad, G. Esmat, H. Abobakr, M. Anwar, and C. Rekacewicz Serum alpha-fetoprotein level predicts treatment outcome in chronic hepatitis C Antivir Ther 12 2007 797 803 (Pubitemid 47235494)
106. R.R. Gad, S. Males, H. El Makhzangy, S. Shouman, A. Hasan, and M. Attala Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C Liver Int 28 2008 1112 1119
107. E.G. Giannini, M. Basso, V. Savarino, and A. Picciotto Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension J Intern Med 266 2009 537 546
108. B. Ramos, M. Núñez, C. Toro, J. Sheldon, J. García-Samaniego, and P. Ríos Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients J Infect 54 2007 173 179 (Pubitemid 46075882)
109. F. Fabrizi, F. Poordad, and P. Martin Hepatitis C infection and the patient with end-stage renal disease Hepatology 36 1 2002 3 10 (Pubitemid 34700756)
110. A. Bruchfeld, K. Lindahl, O. Reichard, T. Carlsson, and R. Schvarcz Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients J Viral Hepat 13 2006 316 321
111. T. Casanovas Taltavull, C. Baliellas Comellas, and J.M. Cruzado Garrit Results of hepatitis C virus treatment in patients on hemodialysis: data from published meta-analyses in 2008 Transplant Proc 41 2009 2082 2084
112. S. Wirth, H. Pieper-Boustani, T. Lang, A. Ballauff, U. Kullmer, and P. Gerner Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C Hepatology 41 2005 1013 1018 (Pubitemid 40593909)
113. P. Jara, L. Hierro, A. de la Vega, C. Díaz, C. Camarena, and E. Frauca Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection Pediatr Infect Dis J 27 2008 142 148
114. S.M. Kamal, A. Ismail, C.S. Graham, Q. He, J.W. Rasenack, and T. Peters Hepatology 39 2004 1721
115. S.M. Kamal, A.E. Fouly, R.R. Kamel, B. Hockenjos, A. Al Tawil, and K.E. Khalifa Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response Gastroenterology 130 2006 632 638 (Pubitemid 43374512)
116. H. Nomura, S. Sou, H. Tanimoto, T. Nagahama, Y. Kimura, and J. Hayashi Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial Hepatology 39 5 2004 1213 1219 (Pubitemid 38569042)
117. A. Inati, A. Taher, S. Ghorra, S. Koussa, M. Taha, and E. Aoun Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection Br J Haematol 130 2005 644 646 (Pubitemid 43899770)
118. Kamal S, Fouly A, Mohamed S, et al. Peginterferon alfa-2b therapy with and without ribavirin in patients with thalassemia: a randomized study. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver, 26-30 April 2006, Austria Center, Vienna, Austria, abstract 585.
119. N. Terrault, and M. Berenguer Treating Hepatitis C infection in liver transplant recipients Liver Transpl 12 8 2006 1192 1204 (Pubitemid 44194586)
120. M. Al Sebayel, H. Khalaf, M. Al Sofayan, M. Al Saghier, A. Abdo, and H. Al Bahili Experience with 122 consecutive liver transplant procedures at King Faisal Specialist Hospital and Research Center Ann Saudi Med 27 2007 1 6
121. A. Yosry, G. Esmat, M. El Serafy, A. Omar, W. Doss, and M. Said Outcome of Living donor liver transplantation for Egyptian patients with hepatitis C (Genotype 4)-related cirrhosis Transplant Proc 40 2008 1481 1484 (Pubitemid 351853138)
122. M.H. Wali, M. Heydtmann, R.F. Harrison, B.K. Gunson, and D.J. Mutimer Outcome of liver transplantation for patients infected by hepatitis C including those infected by genotype 4 Liver Transpl 9 2003 796 804 (Pubitemid 36974945)
123. A. Zekry, P. Whiting, D. Crawford, P. Angus, G. Jeffrey, and R. Padbury Liver transplantation for HCV associated liver cirrhosis: Predictors of outcomes in a population with significant genotype 3 and 4 distribution Liver Transpl 9 2003 339 347 (Pubitemid 36443044)
124. M. Berenguer, M. Prieto, J. Rayon, J. Mora, M. Pastror, and V. Ortiz Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation Hepatology 32 2000 852 858
125. E. Gane, B. Portmann, N. Naoumov, H. Smith, Jm. Underhill, and O. Donaldson Long term outcome of hepatitis C infection after liver transplantation N Engl J Med 20 1996 773 779
126. H. Sugo, G.A. Balderson, D.H. Crawford, J. Fawcett, S.V. Lynch, and R.W. Strong The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation Surg Today 33 2003 421 425 (Pubitemid 36648888)
127. H. Mudawi, A. Helmy, H. Khalaf, H. Al Bahili, Y. Al Shiek, and Y. Medhat Recurrence of hepatitis C virus genotype-4 infection following liver transplantation Annals of Saudi Med 29 2009 91 97
128. A. Yosry, M. Abdel-Rahman, G. Esmat, M. El Serafy, A. Omar, and W. Doss Recurrence of Hepatitis C virus (Genotype 4) infection after living-donor liver transplant in Egyptian patients Exp Clin Transplant 7 2009 157 163
129. Al Hamoudi W, Mohamed H, Kamel Y, Abaalkail F, Al Masri N, Khalaf H, et al. Pegylated Interferon alfa-2a and ribavirin for the treatment of genotype-4 recurrent hepatitis C after liver transplantation. Hepatol Int. 2010;4:S25.
130. M.P. Manns, H. Wedemeyer, and M. Cornberg Treating viral hepatitis C: efficacy, side effects, and complications Gut 55 2006 1350 1359 (Pubitemid 44277369)
131. I. Mederacke, H. Wedemeyer, and M.P. Manns Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection Curr Opin Investig Drugs 10 2009 181 189
132. M.P. Manns, G.R. Foster, J.K. Rockstroh, S. Zeuzem, F. Zoulim, and M. Houghton The way forward in HCV treatment - finding the right path Nat Rev Drug Discov 6 2007 991 1000 (Pubitemid 350201789)
133. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
134. J.G. McHutchison, M.P. Manns, A.J. Muir, N.A. Terrault, I.M. Jacobson, and N.H. Afdhal Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
135. Y. Benhamou, J. Moussalli, V. Ratziu, P. Lebray, V. Gysen, and K. de Backer J Hepatol 50 2009 S6
136. S.D. Seiwert, S.W. Andrews, Y. Jiang, V. Serebryany, H. Tan, and K. Kossen Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) Antimicrob Agents Chemother 52 2008 4432 4441
137. Jensen DM, Wedemeyer H, Herring RW, Ferenci P, Ma MM, Zeuzem S, et al. High rates of early viral response, promising safety profile and lack of
138. M. Elazar, M. Liu, S.A. McKenna, P. Liu, E.A. Gehrig, and J.D. Puglisi The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation Gastroenterology 137 2009 1827 1835
139. J.F. Rossignol, S.M. Kabil, Y. El Gohary, A. Elfert, and E.B. Keeffe Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4 Aliment Pharmacol Ther 28 2008 574 580
140. M.S. Khuroo, M.S. Khuroo, and S.T. Dahab Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4 Aliment Pharmacol Ther 20 2004 931 938 (Pubitemid 39593273)
141. I. Mederacke, and H. Wedemeyer Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges? Ann Hepatol 8 2009 166 168
142. R. Flisiak, S.V. Feinman, M. Jablkowski, A. Horban, W. Kryczka, and M. Pawlowska The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients Hepatology 49 2009 1460 1468
143. P. Ferenci, T.M. Scherzer, H. Kerschner, K. Rutter, S. Beinhardt, and H. Hofer Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy Gastroenterology 135 2008 1561 1567
144. Beinhardt S, Rasoul-Rockenschaub S, Matthias Scherzer T, Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in patient with chronic hepatitis C. J Hepatol. 2010; in press.